Cargando…

Gastroparesis: New insights into an old disease

Gastroparesis (Gp) is a chronic disease characterized by a delayed gastric emptying in the absence of mechanical obstruction. Although this condition has been reported in the literature since the mid-1900s, only recently has there been renewed clinical and scientific interest in this disease, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Usai-Satta, Paolo, Bellini, Massimo, Morelli, Olivia, Geri, Francesca, Lai, Mariantonia, Bassotti, Gabrio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243643/
https://www.ncbi.nlm.nih.gov/pubmed/32476797
http://dx.doi.org/10.3748/wjg.v26.i19.2333
_version_ 1783537443899703296
author Usai-Satta, Paolo
Bellini, Massimo
Morelli, Olivia
Geri, Francesca
Lai, Mariantonia
Bassotti, Gabrio
author_facet Usai-Satta, Paolo
Bellini, Massimo
Morelli, Olivia
Geri, Francesca
Lai, Mariantonia
Bassotti, Gabrio
author_sort Usai-Satta, Paolo
collection PubMed
description Gastroparesis (Gp) is a chronic disease characterized by a delayed gastric emptying in the absence of mechanical obstruction. Although this condition has been reported in the literature since the mid-1900s, only recently has there been renewed clinical and scientific interest in this disease, which has a potentially great impact on the quality of life. The aim of this review is to explore the pathophysiological, diagnostic and therapeutical aspects of Gp according to the most recent evidence. A comprehensive online search for Gp was carried out using MEDLINE and EMBASE. Gp is the result of neuromuscular abnormalities of the gastric motor function. There is evidence that patients with idiopathic and diabetic Gp may display a reduction in nitrergic inhibitory neurons and in interstitial cells of Cajal and/or telocytes. As regards diagnostic approach, 99-Technetium scintigraphy is currently considered to be the gold standard for Gp. Its limits are a lack of standardization and a mild risk of radiation exposure. The C13 breath testing is a valid and safe alternative method. (13)C acid octanoic and the (13)C Spirulina platensis recently approved by the Food and Drug Administration are the most commonly used diagnostic kits. The wireless motility capsule is a promising technique, but its use is limited by costs and scarce availability in many countries. Finally, therapeutic strategies are related to the clinical severity of Gp. In mild and moderate Gp, dietary modification and prokinetic agents are generally sufficient. Metoclopramide is the only drug approved by the Food and Drug Administration for Gp. However, other older and new prokinetics and antiemetics can be considered. As a second-line therapy, tricyclic antidepressants and cannabinoids have been proposed. In severe cases the normal nutritional approach can be compromised and artificial nutrition may be needed. In drug-unresponsive Gp patients some alternative strategies (endoscopic, electric stimulation or surgery) are available.
format Online
Article
Text
id pubmed-7243643
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-72436432020-05-30 Gastroparesis: New insights into an old disease Usai-Satta, Paolo Bellini, Massimo Morelli, Olivia Geri, Francesca Lai, Mariantonia Bassotti, Gabrio World J Gastroenterol Minireviews Gastroparesis (Gp) is a chronic disease characterized by a delayed gastric emptying in the absence of mechanical obstruction. Although this condition has been reported in the literature since the mid-1900s, only recently has there been renewed clinical and scientific interest in this disease, which has a potentially great impact on the quality of life. The aim of this review is to explore the pathophysiological, diagnostic and therapeutical aspects of Gp according to the most recent evidence. A comprehensive online search for Gp was carried out using MEDLINE and EMBASE. Gp is the result of neuromuscular abnormalities of the gastric motor function. There is evidence that patients with idiopathic and diabetic Gp may display a reduction in nitrergic inhibitory neurons and in interstitial cells of Cajal and/or telocytes. As regards diagnostic approach, 99-Technetium scintigraphy is currently considered to be the gold standard for Gp. Its limits are a lack of standardization and a mild risk of radiation exposure. The C13 breath testing is a valid and safe alternative method. (13)C acid octanoic and the (13)C Spirulina platensis recently approved by the Food and Drug Administration are the most commonly used diagnostic kits. The wireless motility capsule is a promising technique, but its use is limited by costs and scarce availability in many countries. Finally, therapeutic strategies are related to the clinical severity of Gp. In mild and moderate Gp, dietary modification and prokinetic agents are generally sufficient. Metoclopramide is the only drug approved by the Food and Drug Administration for Gp. However, other older and new prokinetics and antiemetics can be considered. As a second-line therapy, tricyclic antidepressants and cannabinoids have been proposed. In severe cases the normal nutritional approach can be compromised and artificial nutrition may be needed. In drug-unresponsive Gp patients some alternative strategies (endoscopic, electric stimulation or surgery) are available. Baishideng Publishing Group Inc 2020-05-21 2020-05-21 /pmc/articles/PMC7243643/ /pubmed/32476797 http://dx.doi.org/10.3748/wjg.v26.i19.2333 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Usai-Satta, Paolo
Bellini, Massimo
Morelli, Olivia
Geri, Francesca
Lai, Mariantonia
Bassotti, Gabrio
Gastroparesis: New insights into an old disease
title Gastroparesis: New insights into an old disease
title_full Gastroparesis: New insights into an old disease
title_fullStr Gastroparesis: New insights into an old disease
title_full_unstemmed Gastroparesis: New insights into an old disease
title_short Gastroparesis: New insights into an old disease
title_sort gastroparesis: new insights into an old disease
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243643/
https://www.ncbi.nlm.nih.gov/pubmed/32476797
http://dx.doi.org/10.3748/wjg.v26.i19.2333
work_keys_str_mv AT usaisattapaolo gastroparesisnewinsightsintoanolddisease
AT bellinimassimo gastroparesisnewinsightsintoanolddisease
AT morelliolivia gastroparesisnewinsightsintoanolddisease
AT gerifrancesca gastroparesisnewinsightsintoanolddisease
AT laimariantonia gastroparesisnewinsightsintoanolddisease
AT bassottigabrio gastroparesisnewinsightsintoanolddisease